A study that evaluated over 4000 patients with breast cancer found that, with a median follow-up of 18 years, history of ...

C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer. Nurses are poised to offer a glimpse into integrative medicine ...

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast ...

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as ...

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer. Mastectomy can have major impacts on the life of a person with breast cancer, from body ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know. For young patients with breast cancer, pregnancy ...

Having dealt with difficult-to-diagnose breast cancer herself, Patricia Jakel, MN, RN, AOCN, is all too familiar with the need for vigilant monitoring, even when that goes beyond what is recommended.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...

Samantha Shenoy, NP, MSN, provides nursing guidance on teclistamab/subcutaneous daratumumab’s second-line approval in multiple myeloma. On March 5, the FDA approved ...

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.